ClinicalTrials.gg
CompletedNCT00915837STRIDEUpdated Jun 9, 2023

Safety and Tolerability Study of the Helical Intravitreal Triamcinolone Implant in Diabetic Macular Edema

A Phase 1 interventional study of triamcinolone acetonide and triamcinolone acetonide in Diabetic Macular Edema, sponsored by SurModics, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-09.

Sponsored by SurModics, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing Triamcinolone Acetonide in Macular Edema — 1 open to participants now, 1 under way, none of them phase 3. Triamcinolone Acetonide · Macular Edema.

Enrollment
17th of 25
31 · median 75
Started
2005
with 4 others
Phase 1
5 of 26
1 open now
Registered
11th of 26
by date

Among the 26 studies testing Triamcinolone Acetonide in Macular Edema, this one is the 17th largest by enrollment of the 25 interventional ones that give a count, is one of 5 that started in 2005, is one of 5 in phase 1, and was the 11th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

1 of the 26 studies testing Triamcinolone Acetonide in Macular Edema is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Triamcinolone Acetonide

Triamcinolone Acetonide: first FDA approval 1958 (TRIAMCINOLONE ACETONIDE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing Triamcinolone Acetonide in Macular Edema, or all of them as a file.
02

Study summary

This Phase 1 study will evaluate the safety, tolerability and duration of effect of a helical intravitreal triamcinolone implant for the treatment of diabetic macular edema over a three-year period.

Read the detailed description

The Helical Intravitreal Triamcinolone Implant is intended to provide sustained release of triamcinolone acetonide into the vitreous chamber of the eye.

03

Conditions studied

  • Diabetic Macular Edema

Browse trials for

Keywords

  • DME
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with clinically observable macular edema associated with diabetic retinopathy in study eye
  • Macular edema in study eye is associated with

    1. visual acuity of 20/40 or worse; and
    2. retinal thickening in the fovea as seen on biomicroscopic examination
    3. angiographic evidence of leakage involving the perifoveal capillary net
  • Failure of macular edema to improve with prior macular photocoagulation, or the patient is unlikely to benefit from macular photocoagulation in the opinion of the investigator
  • Patients must be 18 years of age and older
  • Patients must be willing and able to return for scheduled follow up examinations for 3 years after initial surgery.
  • Patients must sign and be given a copy of the written form.

Exclusion criteria

Exclusion Criteria:

  • Monocular, or vision worse than 20/400 in the fellow eye
  • Visual acuity worse than 20/200 20/200 and \< 34 letters read in the study eye
  • Use of depot periocular in the study eye within the past 30 days
  • Current use of >15 mg/day of oral steroids
  • Known steroid responder
  • Ocular hypertension > 22 mmHg in the study eye or need for more than one medication to maintain IOP \< 22 mmHg.
  • Cup to disc ratio of > 0.8 in the study eye
  • Prior filtration surgery or glaucoma implant surgery in the study eye
  • Any active ocular infection in either eye
  • History of herpetic ocular infection in the study eye
  • Macular ischemia, defined as angiographic evidence of enlargement of the foveal avascular zone to 1 disc area or larger, centered on the fovea
  • Macular or panretinal photocoagulation treatment in the study eye within the past 90 days; laser capsulotomy within the past 90 days
  • Planned or known need for ocular surgery in the study eye within 90 days after enrollment and treatment
  • Any condition that precludes the subject's ability to comply with study requirements, including examinations or the completion of the study; or any condition that precludes the examiner's ability to obtain reliable fundus photography, angiography, or OCT images
  • Females who are pregnant or lactating, and premenopausal females who are unwilling to use a medically accepted method of for the duration of the study
  • Participation in another trial within 30 days prior to enrollment or during the study period
  • Uncontrolled hypertension (systolic BP > 160 mm Hg and/or diastolic BP > 90 mmHg)
  • Uncontrolled diabetes ( > 13)
  • Chronic renal failure requiring dialysis or anticipated renal transplant
  • Retinal or choroidal neovascularization in the study eye; anticipated need for panretinal photocoagulation within the next 30 days
  • Macular edema in the study eye known to be due to a cause other than diabetic retinopathy
  • Use of drugs
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Slow release formulation

    Slow release formulation, helical intravitreal triamcinolone implant

    Drug: triamcinolone acetonide

  • Experimental
    fast release formulation

    fast release formulation, helical intravitreal triamcinolone implant

    Drug: triamcinolone acetonide

Interventions

  • Helical intravitreal triamcinolone implant- 925 mcg drug; slow release formulation approximately 1-3 mcg/day

  • Helical intravitreal triamcinolone implant- 925 mcg drug; fast release formulation approximately 3-5 mcg/day

06

What researchers measure

Primary outcomes

  1. Best Corrected Visual Acuity

    Time frame: every 3 months for 36 months

Secondary outcomes

  1. OCT

    Time frame: every 3 months for 36 months

  2. IOP

    Time frame: every 3 months for 36 months

  3. Slit lamp exam/funduscopy

    Time frame: every 3 months for 36 months

  4. Fluorescein angiography

    Time frame: every 3 months for 36 months

  5. Adverse events

    Time frame: every 3 months for 36 months

07

Study locations

4 sites
  • Retinal Consultants of Arizona
    Phoenix, Arizona 85014, United States
  • California Retina Consultants
    Santa Barbara, California 93103, United States
  • Kresege Eye Institute
    Detroit, Michigan 48201, United States
  • VitreoRetinal Surgery, PA
    Edina, Minnesota 55435, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2005, a primary completion of Apr 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2009
First posted
Jun 8, 2009
Start
Jun 2005
Primary completionActual
Apr 2009
CompletionActual
May 2009
Last update
Jun 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00915837
Lead sponsor
SurModics, Inc.
Responsible party
Sponsor
First posted
Jun 8, 2009
Start date
Jun 2005
Primary completion
Apr 2009
Completion
May 2009
Last update
Jun 9, 2023

Study contacts

Herbert L Cantrill, MD
principal investigator · VitreoRetinal Surgery, PA
Pravin U Dugel, MD
principal investigator · Retinal Consultants of Arizona
Tamer H Mahmoud, MD, PhD
principal investigator · Kresege Eye Institute
Robert L Avery, MD
principal investigator · California Retinal Consultants

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Triamcinolone Acetonide

Start the discussion